Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China

Figure 3 Combined positive score and tumor mutation burden level distribution characteristics in colorectal cancer patients. A: Distribution of tumor mutation burden (TMB) levels between homologous recombination deficiency (HRD) and homologous recombination proficient (HRP) groups in all patients; B: Distribution of TMB level between HRD and HRP groups in microsatellite instability-high (MSI-H) patients; C: Distribution of TMB level between HRD and HRP groups in microsatellite-stable (MSS) patients; D: Distribution of combined positive score (CPS) between HRD and HRP groups in all patients; E: Distribution of CPS between HRD and HRP groups in MSI-H patients; F: Distribution of CPS between HRD and HRP groups in MSS patients. ^aP < 0.05; ^bP < 0.01. CPS: Combined positive score; TMB: Tumor mutation burden; CRC: Colorectal cancer; HRD: Homologous recombination deficiency; HRP: Homologous recombination proficient; MSI-H: Microsatellite instability-high; MSS: Microsatellite-stable.